The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications, including acute respiratory distress syndrome, usually due to pneumonia, which increases the risk of developing sepsis. Thus, increasing the need for early diagnosis of sepsis among patients with covid-19 infections. 

[236 Pages Report] The global sepsis diagnostics market size is expected to reach USD 771 million by 2026 from USD 503 million in 2021, at a CAGR of 8.9%. The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness. 

Hospital-acquired infections (HAIs), also known as nosocomial infections, are a major cause of morbidity and mortality worldwide. The most common hospital-acquired infections (HAIs) are urinary tract infections, pneumonia, and sepsis. HAIs can lead to sepsis in immunocompromised patients, geriatric patients, and patients suffering from chronic illnesses.   

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

In the US, the incidence of sepsis among hospitalized patients is rising by 8.7% per year. It is estimated that there are more than 1,000,000 incidences of sepsis among hospitalized patients annually in the nation {Source: CDC, 2018). With the rapid increase in HAIs worldwide, the demand for sepsis diagnostic products is also expected to rise in the coming years. 

Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis. 

Many sepsis diagnostic manufacturers are expanding their product offering in point of care technology rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. . The BACTEC Plus, BacT/Alert, and BACTEC FX blood culturing instruments manufactured by BD Company (US) is an automated microbial detection system offering a rapid diagnosis of sepsis in the turnaround time of three hours. 

The sepsis diagnostics, by product the market is segmented into blood culture media, assays reagent kits, instruments, and software. The blood culture media segment accounted for the largest share of market during the forecast period. This share can be attributed to the growing utilization of blood culture media by hospitals pathology laboratories for the diagnosis of sepsis coupled with an increase in the availability of blood culture media in the market. 

The sepsis diagnostics market, by technology, the market is segmented into bacterial sepsis, viral sepsis, fungal sepsis, and other pathogen. The bacterial sepsis segment accounted for the largest share of market during the forecast period. This share can be attributed to the rise in the bacterial sepsis cases, the increasing number of surgical procedures, and the rising prevalence of HAIs.  

Key Market Players

The prominent players operating in the global sepsis diagnostics market include bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany), EKF Diagnostics (UK), Seegene Inc., (South Korea), Boditech Med (South Korea), Alifax S.r.l. (Italy), AdvanDx  (US), (US), Immunexpress (Australia), and Axis-Shield Diagnostics (UK).